Stephanie Hodson, MD
Hematology & Oncology · Meridian, IDNPI 1265478374
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (33.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Karyopharm Therapeutics Inc. at 29.6% of the total. Reporting peaked in 2023 at $2,050 and has fallen 92.3% since, to $157 in 2024.
Across 111 payments — averaging $49.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$2K
- CTI Biopharma Corp.$1K
- Johnson & Johnson$311
- Genentech USA, Inc.$219
- Amgen$193
- Gilead$158
- plus $2K from 29 others
What the payments were for
- Consulting fees$1,63030%
- Speaking & faculty fees$1,43826%
- Food & beverage$1,85034%
- Education$58311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 1 | $1,630 |
| CTI Biopharma Corp. | 1 | $1,438 |
| Johnson & Johnson | 12 | $311 |
| Genentech USA, Inc. | 12 | $219 |
| Amgen | 10 | $193 |
| Gilead(2 entities) | 6 | $158 |
| Novartis | 7 | $143 |
| AbbVie | 3 | $139 |
| Incyte Corporation | 3 | $125 |
| Agios Pharmaceuticals, Inc. | 1 | $117 |
| Pfizer | 7 | $107 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Foundation Medicine, Inc. | 1 | $92 |
| AstraZeneca | 6 | $75 |
| Sanofi | 5 | $73 |
| Beigene USA, Inc. | 1 | $63 |
| Seagen Inc. | 1 | $62 |
| EMD Serono, Inc. | 3 | $60 |
| Bristol Myers Squibb | 3 | $47 |
| Bayer | 3 | $46 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Lilly USA, LLC | 3 | $35 |
| Eisai Inc. | 2 | $32 |
| Merck | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Sobi, Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $9 |
| Secura Bio, Inc. | 3 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,500 in reported general payments places this provider in the 65th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 31 | $471,017 |
| XtandiEnzalutamide | 31 | $391,599 |
| NubeqaDarolutamide | 15 | $204,645 |
| RevlimidLenalidomide | 14 | $188,836 |
| Abiraterone Acetate | 20 | $78,412 |
| XareltoRivaroxaban | 16 | $14,263 |
| Tamoxifen Citrate | 30 | $1,287 |
| Anastrozole | 75 | $1,264 |
| Hydroxyurea | 36 | $1,063 |
| Letrozole | 34 | $1,000 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $788 |
| Acyclovir | 22 | $416 |
| Prednisone | 18 | $138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $107 | $471,01731 claims |
| BayerNubeqa | $46 | $204,64515 claims |
| Bristol Myers SquibbRevlimid | $47 | $188,83614 claims |
| Johnson & JohnsonXarelto | $311 | $14,26316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Meridian
- Sri Harsha TellaMeridian$8K
- Eric FountainMeridian$47
- Danko MartincicPost Falls$1.1M
- Bobby ChawlaCaldwell$1M
- Christian ShullIdaho Falls$150K
- Dane DicksonRexburg$21K
- Ian QureshiNampa$18K
- Nathan AdamsIdaho Falls$16K
- Andrew KominskyCoeur D Alene$13K
- David BartelsCoeur D Alene$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.